Elsevier, a global leader in evidence-based clinical practice content, research publishing and information analytics, has announced that their evidence-based oncology pathways solution, ClinicalPath, has been approved by the Centers for Medicare & Medicaid Services (CMS) as a clinical guideline for oncology practices participating in the new Enhanced Oncology Model (EOM). With this designation as an approved evidence-based guideline, oncology practices participating in EOM will be able to use ClinicalPath in accordance with the EOM participant redesign, one of the first products of its type to receive such approval.
EOM is a five-year voluntary model for oncology practices, an initiative launched by CMS, a federal agency of the Department for Health and Human Services (HHS). EOM will come into effect on July 1, 2023, with practices opting to participate in EOM being incentivized to consider the whole patient journey and proactively engage with patients.
EOM is CMS’s newest value-based care model, building on the previous Oncology Care Model (OCM), a six-year program that ran from 2016-2022. EOM takes further steps to encourage cancer care to focus more on the patient.
Oncology practices participating in EOM are required to implement participant redesign activities including care planning, use of evidence-based guidelines, use of data for continuous quality improvement, and more. ClinicalPath presents evidence-based oncology pathways embedded in the clinical workflow to help care teams make consistent, well-informed decisions for high-quality care. The associated analytics within ClinicalPath enable accurate tracking of patterns of care and outcomes.
Click here to read the original press release.
